NKX2-8 and ovarian carcinoma: NKX2-8 deletion-reprogrammed fatty acid metabolism contributes to chemoresistance and Perhexiline may be a potential tailored treatment for patients with NKX2-8-deleted epithelial ovarian cancer (94).